Recombinant Human Granulocyte Colony-stimulating Factor Injection(rh-G-CSF\Filgrastim)
Founded in 1997, Shandong Kexing Bioproducts integrates R&D, manufacture, and sales of biopharmaceuticals. Genzon Group and Shenzhen Kexing Biotech are its major stock holders.
The company develops recombinant gene drugs and micro-ecological drugs, to serve the clinical treatment needs of kidney diseases, tumor, and gastrointestinal diseases. It has become a leading player in China's biopharmaceutical industry.